ACAD Nasdaq Pharmaceuticals Financials FY2016βFY2025
Acadia Pharmaceuticals had $1.1B of revenue in fiscal 2025, up 11.9% on the year before. Over five years, revenue changed +19.4% a year on average.
Hi! I read Acadia Pharmaceuticalsβs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+11.9%
Yes. Sales grew 11.9% last year.
Does it make a profit?
36.5%
Yes. It keeps 36.5% of every sale as profit.
Does profit turn into cash?
9.8%
Partly. 9.8% of sales ends up as free cash.
How is the share priced?
8.8x
One share costs 8.8 times its yearly profit per share. Typical for its sector: 28.4x.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days Acadia Pharmaceuticals did it, and the next one. Share prices often move a lot on those days.
Next results
November 4, 2026
Wednesday Β· in 9 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Aug 4, 2026 | Q2 '26 | After the market closes | 8-K β |
| May 6, 2026 | Q1 '26 | After the market closes | 8-K β |
| Jan 13, 2026 | Q4 '25 | During market hours | 8-K β |
| Nov 5, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 6, 2025 | Q2 '25 | After the market closes | 8-K β |
| May 7, 2025 | Q1 '25 | After the market closes | 8-K β |
| Feb 26, 2025 | Q4 '24 | After the market closes | 8-K β |
| Nov 6, 2024 | Q3 '24 | After the market closes | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· Acadia Pharmaceuticals had $1.1B of revenue in fiscal 2025, up 11.9% on the year before. Over five years, revenue changed +19.4% a year on average. Its operating margin was 9.8%, down 14.3Β pts: of every 100 in sales, about 10 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· Acadia Pharmaceuticals made $391M of net profit in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
KIRA Β· Free cash flow was $105M in fiscal 2025, 9.8% of revenue.
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· Acadia Pharmaceuticals returned $0.0M to shareholders in fiscal 2025, 0% of free cash flow. The diluted share count rose 2.1%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· In the last 12 months, insiders sold $2.0M of shares on the open market and bought none.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$2.0M
4 insiders
Of sales under plans
94%
$1.8M
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | Mark C. SchneyerEVP, Chief Financial Officer | Sold plan | 14,292 | $29.22 | $0.4M | Form 4 |
| Aug 5, 2026 | Mark C. SchneyerEVP, Chief Financial Officer | Sold plan | 5,849 | $29.00 | $0.2M | Form 4 |
| Jul 30, 2026 | Elizabeth H.Z. ThompsonEVP, Head of Research & Dev | Sold plan | 16,558 | $26.13 | $0.4M | Form 4 |
| Jun 26, 2026 | James KiharaPrincipal Accounting Officer | Sold plan | 11,421 | $26.08 | $0.3M | Form 4 |
| May 26, 2026 | James KiharaPrincipal Accounting Officer | Sold | 5,401 | $21.18 | $0.1M | Form 4 |
| May 4, 2026 | James KiharaPrincipal Accounting Officer | Sold plan | 1,332 | $21.79 | $0.0M | Form 4 |
| May 4, 2026 | Mark C. SchneyerEVP, Chief Financial Officer | Sold plan | 3,506 | $21.79 | $0.1M | Form 4 |
| Apr 7, 2026 | James KiharaPrincipal Accounting Officer | Sold plan | 1,030 | $22.20 | $0.0M | Form 4 |
| Apr 7, 2026 | Mark C. SchneyerEVP, Chief Financial Officer | Sold plan | 2,709 | $22.20 | $0.1M | Form 4 |
| Mar 26, 2026 | James KiharaPrincipal Accounting Officer | Sold plan | 1,109 | $21.65 | $0.0M | Form 4 |
| Mar 26, 2026 | Mark C. SchneyerEVP, Chief Financial Officer | Sold plan | 3,208 | $21.65 | $0.1M | Form 4 |
| Mar 25, 2026 | Adams Catherine OwenChief Executive Officer, Director | Sold plan | 11,641 | $21.47 | $0.2M | Form 4 |
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably Acadia Pharmaceuticals can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $521M | $417M | $439M | $756M | $820M |
| Current ratio | 6.4x | 4.0x | 2.4x | 2.4x | 3.8x |
| Quick ratio | 6.3x | 4.0x | 2.3x | 2.1x | 3.4x |
| Total assets | $700M | $588M | $749M | $1.2B | $1.6B |
| Total liabilities | $159M | $187M | $317M | $455M | $337M |
| Shareholders' equity | $541M | $400M | $432M | $733M | $1.2B |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | β | β | β |
| Cash from operations is positive | β | β | β |
| Return on assets rose | β | β | β |
| Cash from operations exceeds net income | β | β | β |
| Debt fell relative to assets | β | β | β |
| Current ratio rose | β | β | β |
| Share count didn't rise | β | β | β |
| Gross margin rose | β | β | β |
| Revenue rose relative to assets | β | β | β |
| F-score | β / 9 | β / 9 | β / 9 |
| Accruals ratio | β11.7% | 7.1% | 20.4% |
| Altman Z'' | β6.64 | β0.05 | 3.79 |
What does the share cost, and how does it compare?
KIRA Β· At $19.73 a share, the company is worth $3.4B: 8.8 times its earnings of the last four quarters.
Change the assumptions and see what they imply per share. These are models, not forecasts or price targets β the answer depends entirely on what you put in.
In plain words: Move the sliders to try your own guesses about growth. The result is what one share would be worth if those guesses came true. Different guesses give very different answers.
Value per share
β
Adds net cash of β and divides by 169.9M diluted shares. Ten years of cash flows plus a terminal value, discounted to today.
Value per share
β
Reference multiples: today 8.8x Β· peers 17.1x Β· sector 28.4x.
KIRA Β· Acadia Pharmaceuticals grew sales faster than 2 of its 4 similar companies. Its P/E is higher than 0 of 4.
Each companyβs latest fiscal year. Fiscal years end in different months, so periods donβt line up exactly.
In plain words: The same numbers for similar companies, so you can tell whether a figure is high or low for this kind of business.
| Company | Market cap | Growth | Op. margin | FCF margin | ROIC | P/E | F-score | |
|---|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals ACAD | $3.4B | 11.9% | 9.8% | 9.8% | β | 8.8x | β | |
| Indivior INDV | $4.3B | 4.3% | 21.2% | β7.5% | β | 12.4x | 4 | Compare β |
| ANI Pharmaceuticals ANIP | $1.6B | 43.8% | 12.6% | 19.4% | 15.9% | 15.7x | 6 | Compare β |
| Collegium Pharmaceutical COLL | $746M | 23.6% | 23.0% | 42.0% | 53.4% | 18.5x | 6 | Compare β |
| Alkermes ALKS | $7.6B | β5.3% | 17.2% | 32.6% | β | 114.8x | β | Compare β |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $17.3M | $125M | $224M | $339M | $442M | $484M | $517M | $726M | $958M | $1.1B |
| Gross profit | $14.3M | $116M | $211M | $328M | $432M | $473M | $507M | $685M | $876M | $983M |
| Research and development | $99.3M | $149M | $187M | $240M | $319M | $239M | $362M | $352M | $303M | $329M |
| Operating income | β$273M | β$292M | β$247M | β$247M | β$287M | β$170M | β$224M | β$73.4M | $231M | $105M |
| Pretax income | β$270M | β$288M | β$244M | β$234M | β$281M | β$168M | β$213M | β$51.0M | $258M | $139M |
| Income tax | $1.3M | $1.1M | $1.3M | $0.9M | $0.6M | $0.4M | $2.5M | $10.2M | $31.6M | β$252M |
| Net income | β$271M | β$289M | β$245M | β$235M | β$282M | β$168M | β$216M | β$61.3M | $227M | $391M |
| Diluted EPS | β$2.34 | β$2.36 | β$1.94 | β$1.60 | β$1.79 | β$1.05 | β$1.34 | β$0.37 | $1.36 | $2.30 |
| Diluted shares | 0.12B | 0.12B | 0.13B | 0.15B | 0.16B | 0.16B | 0.16B | 0.16B | 0.17B | 0.17B |
| Cash flow | ||||||||||
| Cash from operations | β$208M | β$218M | β$168M | β$151M | β$136M | β$126M | β$114M | $16.7M | $158M | $110M |
| Capital expenditure | $1.5M | $0.8M | $2.1M | $1.1M | $7.6M | $1.1M | $0.0M | $0.0M | $0.5M | $4.7M |
| Free cash flow | β$210M | β$219M | β$170M | β$152M | β$144M | β$127M | β$114M | $16.7M | $157M | $105M |
| Depreciation and amortization | $1.8M | $2.7M | $3.0M | $2.8M | $2.9M | $3.3M | $2.0M | $5.6M | $15.9M | $11.8M |
| Stock-based compensation | $55.3M | $75.5M | $81.6M | $82.3M | $84.4M | $63.6M | $68.2M | $66.4M | $67.0M | $52.1M |
| Acquisitions | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Share buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends paid | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Dividends and buybacks | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $529M | $341M | $474M | $697M | $632M | $521M | $417M | $439M | $756M | $820M |
| Finance lease liabilities | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Current assets | $548M | $374M | $526M | $760M | $718M | $618M | $508M | $616M | $938M | $1.1B |
| Current liabilities | $42.6M | $49.0M | $59.6M | $74.8M | $106M | $96.1M | $126M | $254M | $395M | $277M |
| Inventory | $4.2M | $5.2M | $4.1M | $6.3M | $9.7M | $14.1M | $11.6M | $40.4M | $91.7M | $111M |
| Property and equipment, net | $3.1M | $2.7M | $3.3M | $3.2M | $9.2M | $8.0M | $6.0M | $4.6M | $4.2M | $7.5M |
| Total assets | $561M | $385M | $540M | $783M | $783M | $700M | $588M | $749M | $1.2B | $1.6B |
| Total liabilities | $42.7M | $49.2M | $61.1M | $84.0M | $156M | $159M | $187M | $317M | $455M | $337M |
| Shareholders' equity | $518M | $335M | $479M | $699M | $627M | $541M | $400M | $432M | $733M | $1.2B |
| Margins | ||||||||||
| Gross margin | 82.2% | 92.7% | 94.5% | 96.7% | 97.7% | 97.8% | 98.0% | 94.3% | 91.5% | 91.7% |
| Operating margin | β1,574.1% | β234.1% | β110.6% | β72.7% | β64.9% | β35.2% | β43.2% | β10.1% | 24.1% | 9.8% |
| EBITDA margin | β1,563.6% | β231.9% | β109.2% | β71.9% | β64.2% | β34.5% | β42.8% | β9.3% | 25.8% | 10.9% |
| Net margin | β1,565.9% | β231.7% | β109.6% | β69.4% | β63.7% | β34.7% | β41.8% | β8.4% | 23.6% | 36.5% |
| FCF margin | β1,211.2% | β175.0% | β75.8% | β44.9% | β32.5% | β26.2% | β22.1% | 2.3% | 16.4% | 9.8% |
| Returns | ||||||||||
| Return on capital employed | β75.9% | β68.5% | β60.6% | β41.5% | β41.4% | β26.6% | β41.9% | β15.3% | 35.9% | 10.1% |
| Return on equity | β75.6% | β67.8% | β60.2% | β39.9% | β42.5% | β28.8% | β45.9% | β14.7% | 38.9% | 39.9% |
| Return on assets | β69.3% | β61.2% | β53.0% | β35.6% | β36.0% | β22.6% | β33.5% | β9.2% | 23.4% | 28.4% |
| Growth | ||||||||||
| Revenue growth | 28,311.5% | 620.7% | 79.2% | 51.5% | 30.3% | 9.6% | 6.8% | 40.5% | 31.9% | 11.9% |
| Net income growth | β | β | β | β | β | β | β | β | β | 72.7% |
| EPS growth | β | β | β | β | β | β | β | β | β | 69.1% |
| FCF growth | β | β | β | β | β | β | β | β | 844.0% | β33.1% |
| Share count change | 15.1% | 5.8% | 3.3% | 16.3% | 6.9% | 2.0% | 0.7% | 1.3% | 1.6% | 2.1% |
| Financial health | ||||||||||
| Current ratio | 12.9x | 7.6x | 8.8x | 10.2x | 6.8x | 6.4x | 4.0x | 2.4x | 2.4x | 3.8x |
| Quick ratio | 12.8x | 7.5x | 8.8x | 10.1x | 6.7x | 6.3x | 4.0x | 2.3x | 2.1x | 3.4x |
| Capital allocation | ||||||||||
| Capex / revenue | 8.7% | 0.7% | 0.9% | 0.3% | 1.7% | 0.2% | 0.0% | 0.0% | 0.1% | 0.4% |
| Stock comp / revenue | 318.9% | 60.5% | 36.4% | 24.3% | 19.1% | 13.1% | 13.2% | 9.1% | 7.0% | 4.9% |
| Payouts / FCF | β | β | β | β | β | β | β | 0.0% | 0.0% | 0.0% |
| Quality scores | ||||||||||
| Altman Z'' | 10.0 | β2.8 | 2.0 | 5.3 | β1.4 | β3.2 | β9.2 | β6.6 | β0.1 | 3.8 |
| Accruals ratio | β16.1% | β15.2% | β16.8% | β12.7% | β18.6% | β5.7% | β15.8% | β11.7% | 7.1% | 20.4% |
Source: SEC EDGAR XBRL filings (CIK 0001070494). Data updated October 22, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
